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SummARy – depression pharmacotherapy can be described with weak predictability of in-
dividual response. Antidepressants are prescribed based on trial and error, as it is not possible to 
determine which patients will respond to antidepressants. it would appear that pharmacogenetics 
is the most promising path towards achieving the goal of individualized therapy. today, the most 
commonly prescribed antidepressants are those from the group of selective serotonin reuptake in-
hibitors (SSRi). The most investigated genetic variations in the prediction and individualization of 
antidepressant therapy is the serotonin transporter gene (5-HttLpR). The objective of this paper is 
to provide an overview of the research to date on 5-HttLpR polymorphism in response to SSRi. 
This paper gives an overview of 35 studies investigating the efficacy of SSRi antidepressants in 
dependence of 5-HttLpR polymorphism. The results of three meta-analyses examining this issue 
are discussed. briefly, the great majority of studies conducted have shown that L-allele carriers have 
a faster and better response to SSRi antidepressants, if they are Caucasians. Studies with negative 
results included ethnically mixed populations, and it is known that there are different allele frequ-
encies among ethnic groups and the consequence of this are the varying results of pharmacogenetic 
studies. pharmacogenetic analysis of 5-HttLpR polymorphism has proven to be economically 
cost-effective considering the recurrent course of the disease. it would appear that the response to 
SSRi antidepressants and the development of adverse reactions are associated with 5-HttLpR 
polymorphism in Caucasians and this pharmacogenetic analysis could be one of the first in future 
clinical practice.
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Introduction
depressive disorder is one of the most significant 
psychiatric disorders. it is believed that this disor-
der will become the second leading cause of death or 
disability by 2020, immediately after cardiovascular 
disease1,2. depressive disorder can appear as a single 
episode, or can occur episodically, and there is a life-
long diagnosis with numerous consequences to physi-
cal and mental health and social wellbeing. it can also 
be fatal, as many suffering from the disease commit 
suicide3,4. depression of moderate to serious intensity 
is treated with different types of antidepressants, from 
the earlier cyclical structures or monoamine oxidase 
inhibitors, to more recent formulas that selectively act 
on monoamine transporters (serotonin, noradrenaline 
or dopamine), individually or in different transporter 
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combinations5,6. Antidepressants acting on serotonin 
and/or noradrenaline receptors are less common. 
However, regardless of the receptor profile, the key 
common mechanism of activity of all antidepressants 
is the increase of synaptic concentrations of monoam-
ines, irrespective of the subgroup. All antidepressants, 
with the exception of monoamine oxidase inhibitors 
or noradrenergic and specific serotoninergic antide-
pressants, act on one of the monoamine transporters, 
usually serotonin transporter5,6. in recent decades, the 
most commonly prescribed and administered group 
of antidepressants are the selective serotonin reuptake 
inhibitors (SSRi), such as citalopram/escitalopram, 
fluoxetine, fluvoxamine, paroxetine and sertraline7. 
However, although SSRi antidepressants have been 
confirmed as efficient drugs for the treatment of de-
pressive disorder, there remains much room for im-
provement. for example, a large number of patients 
with depressive disorder only partially respond to an-
tidepressants, 30%-40% of patients with depressive 
disorder do not achieve therapeutic response to the 
first use of antidepressants, and 60%-70% of patients 
do not go into remission8. in addition to the frequent 
treatment failure, antidepressant therapy can have 
a delayed start to the clinical effect of up to several 
weeks. This delay is even longer if the first application 
of the antidepressant fails to have effect, so a second 
antidepressant is given, but only after 4-6 weeks, the 
length of time necessary to observe the clinical effect of 
the drug. This prolongs the patient’s recovery time by 
several weeks, which can lead to clinical worsening of 
symptoms and early withdrawal from treatment9. This 
further burdens the patient and prolongs his suffering, 
as well as increasing the costs of extended treatment 
or due to absenteeism, and the like1-4. unfortunately, 
there is no test to help determine which patients will 
react well to the administration of antidepressants. 
medical history and clinical data on the patient have 
not proven promising in this respect10,11. with the 
development of pharmacogenetics in recent years, in-
dividualized therapy has been made possible in sev-
eral areas of medicine. with regard to individualized 
antidepressant therapy in the treatment of depressive 
patients, the research to date has shown that the vari-
ability of response among patients may be associated 
with genetic, metabolic and environmental factors12,13. 
Since antidepressants are metabolized via the cyto-
chrome system, there have been many studies to test 
the polymorphism of the cytochrome system gene and 
the response to antidepressant therapy14. These studies 
have been based on pharmacokinetics. The second type 
of study is based on pharmacodynamics15,16. Since the 
majority of antidepressants, i.e. the most commonly 
used antidepressants, the SSRi antidepressants, act 
on the serotonin transporters, their effect is achieved 
through the inhibition of serotonin reuptake into the 
neuron by acting on serotonin transport, and to date 
the largest number of pharmacogenetic studies have 
addressed the serotonin transporter.
Serotonin Transporter Gene
The serotonin transport gene is positioned at the 
SCL6A4 gene locus on chromosome 17 (17q11.1-
17q12) and encompasses ∼31 kpb, consisting of 14 ex-
ons (18) and is commonly labeled as 5-Htt or SeRt. 
This gene produces the protein that transports sero-
tonin from the synapse back into the neuron following 
neural stimulation. Since it moderates the rapid re-
moval and recycling of the liberated serotonin, SeRt 
plays a critical role in the homeostatic regulation of 
the strength, duration and spatial distribution of the 
signal reaching the serotonin receptors17.
The commonly described polymorphism of SeRt 
is a variable number of tandem repeats (vntR) in 
the second intron (Stin2), which consists of four vari-
ations with 9 (Stin2.9), 10 (Stin2.10), 11 (Stin2.11) 
or 12 (Stin2.12) copies of the 17-pb tandem repeats. 
The most common alleles of this polymorphism are 
Stin2.10 and Stin2.12. Stin12 is labeled as the “l” 
(long) allele, while the remaining variations are la-
beled as the “s” (short) alleles. This polymorphism 
is positioned outside the coding region (exon) of the 
SeRt gene, although it is assumed that it affects the 
regulatory element of gene transcription18.
However, the most extensively studied gene varia-
tion of 5-Htt is the insertion/deletion polymorphism 
in the SeRt promoter region, which is the subject 
of this review. it is made with the deletion of the 43 
or 44 bases. in the literature, this insertion/deletion 
promoter polymorphism is most often called 5-Ht-
tLpR or SeRt. The variations of this insertion/de-
letion polymorphism are usually classified into two 
categories, long allele (l) with 16, 18 or 20 repeating 
fragments, and the short allele(s) with 14 repeating 
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fragments. The presence of this s-allele is associated 
with weaker gene activity, i.e. with a fewer number 
of serotonin transporters on the neuron membrane 
and the consequential reduced ability to reuptake se-
rotonin into the neuron from the synapse14,19. for this 
polymorphism, there is a significant difference in the 
allele frequency among races. The l-allele is present in 
Asians at a lower frequency than in Caucasians. for 
example, the L/L genotype is present in 29%-43% of 
Caucasians, and only in 1%-13% of Asians. further-
more, the s-allele is present in 42% of Caucasians, but 
can be found in up to 78% of Asians. And finally, the 
S/S genotype varies from 21.6%-28.3% in Caucasians, 
as compared to 55.6%-60% in Asians20-22.
Overview of Current Studies on the 5-HTTLPR 
Polymorphism and SSRI Efficacy
to conduct this overview, we used the pubmed, 
SCopuS and iSi web of knowledge databases us-
ing the key words SERT, 5-HTT, SLC6A4, serotonin 
transporter gene, 5-HTTLPR with the key words an-
tidepressants, selective serotonin reuptake inhibitors and 
SSRIs. The references in the papers recovered were 
also searched in order to find additional research. pa-
pers not written in english were not considered. A 
total of 35 studies and 3 meta-analyses in the period 
from 1998 to January 2012 were found to examine the 
efficacy of SSRi in dependence with the polymor-
phism of 5-HttLpR. The results of all studies are 
shown in Appendix 1. The research results are divided 
based on the ethnicity of subjects, i.e. divided into 
studies conducted on Caucasians, on Asians and on 
mixed populations. A total of 8,424 subjects were in-
cluded in the studies. in Appendix  1 it is evident that 
in the research conducted on Caucasians, a high num-
ber of studies were found that demonstrated a higher 
efficacy of SSRi antidepressants if the subject was an 
l-allele carrier or was the L/L genotype, depending 
on the study23-32,34,36,38,39. only 3 of 17 studies did not 
find an association between the alleles or genotypes of 
5-HttLpR and the efficacy of SSRi33,35,37. Consid-
ering the studies conducted on mixed racial popula-
tions, the majority did not find an association between 
the alleles or genotypes of 5-HttLpR and the ef-
ficacy of SSRi (6 of 9 studies were negative)40,42-45,48. 
Research conducted on Asian subjects gave contradic-
tory results. Some studies showed a greater efficacy 
of SSRi antidepressants if the subject was an s-allele 
carrier and/or S/S genotype (4 of 9 studies)49,50,55,56, 
while other studies gave the same results as in Cauca-
sians (3 of 9 studies)51,53,54, and one study failed to find 
any link between the SSRi efficacy and 5-HttLpR 
polymorphism57. one study investigated adverse reac-
tions without positive results52. 
to date, three meta-analyses have been conducted 
on the efficacy of antidepressants with regard to the 
5-HttLpR polymorphism58-60. of these, two found 
a positive effect of 5-HttLpR polymorphism on the 
response and remission in patients treated with SSRi 
antidepressants58,59. The third study did not find any 
link between the 5-HttLpR polymorphism and the 
efficacy of SSRi antidepressants60. However, the lat-
ter meta-analysis had a serious methodological error, 
since the results of all studies were analyzed irrespec-
tive of ethnicity. it is well known that Asians have dif-
ferent 5-HttLpR allele frequencies than Caucasians 
(for details see introduction and discussion). fur-
thermore, the meta-analysis with the negative result is 
methodologically limited and uses a meta-regression 
approach that is of limited strength.
Discussion
pharmacogenetics is currently one of the most 
promising areas in psychiatric research. The objective 
of pharmacogenetics is to detect genetic factors that 
determine variation in the clinical response and/or 
adverse reactions to a certain psychopharmacothera-
py, and to select the best possible therapy for an indi-
vidual patient based on genetic analysis of the subject’s 
various genes61. dozens of studies have shown that 
the efficacy of SSRi antidepressants is associated with 
5-HttLpR polymorphism, and that l-allele carri-
ers will have better response to SSRi antidepressants 
than s-allele carriers. However, the above is valid 
exclusively for Caucasians, while the opposite is the 
rule for Asians, i.e. s-allele carriers will have better 
response than l-allele carriers. These claims have also 
been confirmed by two meta-analyses, while a third 
one did not confirm these findings. However, the me-
ta-analyses with the negative result contained several 
methodological errors, primarily that consideration 
to ethnicity was not given in the analysis, although 
it is known that this is an important hindering factor 
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in pharmacogenetic research due to the very differ-
ent allele frequencies among races. for example, the 
L/L genotype is present in 29%-43% of Caucasians 
but only in 1%-13% of Asians, while the S/S genotype 
varies from 21.6%-28.3% in Caucasians, as compared 
to 55.6%-60% in Asians.
Several facts must be outlined for the individual 
studies giving negative results. in one study, the sub-
jects were treated with various classes of antidepres-
sants, including SSRi antidepressants33. As previously 
stated, the effects of SSRi antidepressants are best 
associated with 5-HttLpR polymorphism. in that 
study, when a sub-analysis was conducted only with 
SSRi antidepressants, a better response was found in 
those patients carrying the l-allele. The study also in-
cluded a heterogeneous group of subjects, both with 
initial episodes of the disease and those with thera-
peutically resistant cases. in our opinion, separate 
analyses should have been conducted for patients with 
therapeutically resistant cases from those subjects who 
were not resistant to therapy. A second study with 
negative findings had only 64 subjects, which resulted 
in low strength to prove the effect of the S/S geno-
type. Considering the frequency of the S/S genotype 
is about 13%, in this study only a few of the subjects 
had this genotype35. finally, the study showing no 
connection between the efficacy of SSRi and 5-Ht-
tLpR polymorphism showed that subjects carrying 
the s-allele had an increased incidence of adverse re-
actions to SSRi antidepressants, which is in line with 
the remaining studies38. The increased risk of devel-
oping adverse reactions in s-allele carriers can lead to 
reduced cooperation in treatment, and therefore, can 
diminish the clinical effect.
The remaining studies with negative findings on 
the link between the efficacy of SSRi antidepres-
sants and 5-HttLpR polymorphism were conduct-
ed on mixed racial populations (Caucasians, Asians, 
etc.), and for the above reasons, these studies could 
not have yielded positive results, while the negative 
findings cannot be interpreted as a diminished link 
between the efficacy of SSRi antidepressants and 
5-HttLpR polymorphism. instead, they need to be 
regarded through the different and opposing effects of 
individual 5-HttLpR genotypes among Caucasians 
and Asians40-48. with regard to the studies conducted 
on the Asian population, the findings are contradic-
tory and the effect of 5-HttLpR on the response 
to antidepressants appears weak49-57. furthermore, a 
potential reason for discordance among findings in 
individual studies is the fact that a polymorphism of 
the l-allele (rs25531A/g) was recently discovered, i.e. 
the g variation (Lg) that results in reduced expression 
of the gene that is equivalent to the expression in the 
s-allele62. This relevant study implies the need for re-
examination of all previous research. The research to 
date has shown that in addition to the different allele 
frequencies of 5-HttLpR among ethnicities, the 
contradictory effect of 5-HttLpR on the response 
to SSRi is also due to various sociodemographic and 
clinical variables that are potential stratification fac-
tors10,11. in future studies, it will be necessary to test 
the interaction between sociodemographic and clini-
cal variables with 5-HttLpR63. for example, studies 
conducted according to patient age have proven to be 
contradictory; some authors claim that the response 
to antidepressants increases with age for l-allele car-
riers, while this is not corroborated by other stud-
ies27,64. furthermore, studies investigating the effects 
of gender on the clinical response to treatment with 
SSRi with regard to individual genotypes of 5-Ht-
tLpR are contradictory36,65,66. various clinical factors 
such as the type of depression (melancholic or atypi-
cal), seasonality, initial episode versus chronic forms, 
etc., can also impact the response to antidepressants, 
depending on the 5-HttLpR genotype67,68. Special 
attention should also be paid to personality traits, as 
it has been shown that anxiety, neuroticism or harm-
avoidance characteristics are also linked to 5-Ht-
tLpR polymorphism63,69. 
Studies investigating the cost-effectiveness of 
5-HttLpR genotyping therapy for depressive dis-
order are also interesting. According to this research, 
the selection of antidepressants based on the results of 
5-HttLpR genotyping can be a cost-effective solu-
tion in high-income countries, while this is not con-
firmed for middle-income countries due to the costs 
of genotyping70. Another study also showed the cost-
effectiveness of 5-HttLpR genotyping in the selec-
tion of antidepressants with regard to other recurrent 
depressive episodes71. 
And the last but not the least, there are impor-
tant ethical dilemmas surrounding pharmacogenetic 
testing, particularly in the risk to benefit ratio of the 
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knowledge of genotypes. for example, will carriers 
of mutant genotypes be treated differently in advance 
or will they perhaps be subjected to additional, un-
necessary risks or denied routine therapy? will these 
patients receive different treatment from health insur-
ance companies in the future? Another important is-
sue is the keeping of dnA72. Considering that, labora-
tories and pharmaceutical industry are technologically 
prepared to produce commercial pharmacogenetic 
kits, the likes of which already exist in the field of 
psychiatry at the pharmacokinetic level, without men-
tion of the details of this technology, particularly in 
psychiatry. 
in conclusion, treatment with antidepressants, in-
cluding SSRi, is based on the trial and error principle. 
The clinical characteristics of depressive disorder are 
not sufficient for the selection of antidepressants, and 
pharmacogenetics appears to be a promising path 
forward towards achieving the goal of individualized 
therapy. The current findings of the effects of 5-Ht-
tLpR genotyping on the efficacy of SSRi antidepres-
sants among Caucasians can be useful in the selection 
of SSRi antidepressants. However, at present, the 
introduction of 5-HttLpR genotyping is expected 
to be used only in special situations. if the findings 
to date can be confirmed, at least for the Caucasian 
population, we can soon expect to see the first phar-
macogenetic test for antidepressants.
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Sažetak
poLimoRfiZAm genA ZA SeRotoninSki tRAnSpoRteR (5-HttLpR) i učinkovitoSt 
SeLektivniH inHibitoRA ponovne poHRAne SeRotoninA – imAmo Li dovoLJno 
dokAZA ZA kLiničku pRAkSu
D. Karlović i A. Serretti
farmakoterapija depresije mogla bi se opisati slabom predvidljivosti individualnog odgovora. Antidepresivi se ordi-
niraju po načelu slučaj ili pogreška, jer kliničkim značajkama ne uspijevamo odrediti koji će bolesnik odgovoriti na an-
tidepresive ili razviti nuspojave. čini se da je farmakogenetika put koji najviše obećava kako bi se postigao zadani cilj, 
individualizirana terapija. danas se najčešće primjenjuju antidepresivi iz skupine selektivnih inhibitora ponovne pohrane 
serotonina (SSRi). S druge strane, najistraživanija genetska varijanta u predviđanju i individualizaciji antidepresivne te-
rapije je polimorfizam gena za serotoninski transporter (5-HttLpR). Cilj ovoga rada je prikazati dosadašnja istraživa-
nja polimorfizma 5-HttLpR i odgovora na SSRi. u radu je prikazano 35 studija u kojima se istraživala učinkovitost 
antidepresiva SSRi u ovisnosti o polimorfizmu 5-HttLpR. prikazani su i rezultati 3 meta analize koje su istraživale 
navedenu problematiku. ukratko, velika većina dosadašnjih studija je pokazala da nosioci L alela imaju brži i bolji odgovor 
na antidepresive SSRi ako su bijelci. navedeno potvrđuju i 2 meta analize. Studije koje su bile negativne imale su etnički 
miješanu populaciju, a zna se da su frekvencije alela drugačije kod različitih etničkih skupina i posljedično tome i različiti 
rezultati farmakogenetskih istraživanja. Za Azijate rezultati su još proturječni. farmakogenetska analiza polimorfizma 
5-HttLpR se pokazala i ekonomski isplativa ako se uračuna rekurentni tijek bolesti. čini se da su odgovor na antide-
presive SSRi i razvoj nuspojava povezani s polimorfizmom 5-HttLpR u bijelaca i navedena farmakogenetska analiza bi 
mogla biti jedna od prvih u budućoj psihijatrijskoj kliničkoj praksi. 
ključne riječi: Farmakogenetika; Polimorfizam gena za serotoninski transporter; Selektivni inhibitori ponovne pohrane se-
rotonina
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